Reata Pharmaceuticals Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Reata Pharmaceuticals Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 30 Nov 2022 | Lorem |
| Reata’s Omaveloxolone Prompts Experts to Seek Longer-Term Data in Friedreich’s Ataxia with Likely FDA Approval on the Way | 10 Nov 2022 | William Newton |
| Pulmonary hypertension diagnosis changes spark debate on trial inclusion criteria for clinical trials; off-label drug use needs better definition | 29 May 2019 | Manasi Vaidya |
| Reata’s bardoxolone methyl in final stretch of pivotal CTD-PAH study with approximately 10% accrual left, source says | 24 May 2019 | Manasi Vaidya |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward